Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: A new role for TNF alpha?

Microscopy Research and Technique

Volumn 50, Issue 3, 2000, Pages 251-257

  Sivaraman, S ^a   Deshpande, C G ^a   Ranganathan, R ^a   Huang, X ^a   Jajeh, A ^b   O'Brien, T ^a   Huang, R W ^c   Gregory, S A ^a   Venugopal, P ^a   Preisler, H D ^a  

^a RUSH CANCER INSTITUTE   (United States)

^b Jr Hospital of Cook County   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B cell lymphoma; CD20; Cytokines; Tumor necrosis factor; Upregulation

Indexed keywords

CYTOLOGY; DISEASES; GLYCOPROTEINS; MACROPHAGES; ONCOLOGY; TUMORS;

ANTIBODY THERAPY; B CELLS; B-CELL LYMPHOMA; CD20; CHRONIC LYMPHOCYTIC LEUKEMIAS; CYTOKINES; IN-VITRO; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS; UP-REGULATION;

MONOCLONAL ANTIBODIES;

CD20 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0034254532     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20000801)50:3<251::AID-JEMT9>3.0.CO;2-7     Document Type: Article

References (33)

1. Anderson KC, Bates MP, Slaughernhoupt BL, Pinkus GS, et al. 1984. Expression of human B cell-associated antigens on leukemias and lymphomas. A model of human B cell differentiation. Blood 63: 1424-1433.
2. Blick M, Sherwin SA, Rosenblum M, Gutterman J. 1987. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986-2989.
3. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. 1975. An endotoxin induced factor that causes necrosis of tumor. Proc Natl Acad Sci USA 72:3666.
4. Clark EA, Shu G. 1987. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. J Immunol 138:720-725.
5. Cordingley FT, Hoffbrand AV, Heslop HE, Turner M, Bianchi A, Reittie JE, Vyakarnam A, Meager, Brener MK. 1988. Tumor necrosis factor as an autocrine tumor growth factor for chronic B-cell malignancies. Lancet 969-971.
6. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B 1997. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Chemother Radiopharmaceut 12:177-186.
7. Digel W, Stefanic M, Schoniger W, Buck C, Raghavachar A, Frickhofen N, Porzsolt F. 1989. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 73:1242-1246.
8. Digel W, Porzsolt F, Schmid M, Hermann F, Lesslauer W, Brockhaus M. 1992. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 89:1690-1693.
9. Dighiero G., Travade P, Chevret S, Fenaux P, et al. 1991. B Cell chronic lymphocytic leukemia: present status and future directions. Blood 78:1901-1914.
10. Foa R, Massaia M, Cardona S, Tos AG, Bianchi A, Attisano C, Guarini A, di Celle PF, Fierro MT. 1990. Production of tumor necrosis factor alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease. Blood 76:393-400.
11. Heilig B, Mapara M, Brockhaus M, Krauth K, Dorken B. 1991. Two types of TNF receptors are expressed on human normal and malignant B lymphocytes. Clin Immunol Immunopathol 61:260-267.
12. Jabbar SA, Hoffbrand AV, Wickremasinghe GR.1994. Br J Haematol 86:496-504.
13. Jansen JH, Wientjens GJ, Willemze R, Kluin-Nelemans JC. 1992. Production of tumor necrosis factor alpha by normal and malignant B lymphocytes in response to interferon alpha, interferon gamma and interleukin-4. Leukemia 6:116-119.
14. Jelinek DF, Lipsky PE. 1987. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor alpha and interleukin1. J Immunol 139:2970-2976.
15. Kohase M, Henrikson-Destefano D, May LT, Vilcek J, Sehgal PB.1986. Induction of B3 interferon by tumor necrosis factor: A homeostatis mechanism in the control of cell proliferation. Cell 45:659-669.
16. Kronke M, Schutze S, Scheurich P, Meichle A, Hensel G, Thoma B, Krupa G and Pfizenmaier K.1990. Tumor necrosis factor signal transduction. Cell Signal 2:1-8.
17. Larsson LG, Carlsson M, Schena M, Lantz M, Caligaris-Cappio F, Nilason K. 1993. Interleukin -2 enhances the production of tumor necrosis factor alpha in activated B type chronic lymphocytic leukemia (B-CLL) cells. Leukemia 7:226-234.
18. McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, et al. 1998. Rituximab Chimeric Anti CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half the patients respond to a four dose treatment program. J Clin Oncol 16:2825-2833.
19. Old LJ. 1985. Tumor necrosis factor. Science 230:630-632.
20. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al., 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445.
21. Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV. 1996. Interleukin-6 inhibits apoptosis and tumor necrosis factor induced proliferation of B chronic lymphocytic leukemia. Leuk Lymph 22:83-90.
22. Rieckman P, D'Alessandro F, Nordon RP, Fauci AS, Kehrl JH. 1991. IL-6 and tumor necrosis factor alpha. Autocrine and paracrine cytokines involved in B cell function. J Immunol 146:3462-3468.
23. Sceurich P, Thoma B, Ucer U, Pfizenmaier K. 1987. Immunoregulatory activity of recombinant human tumor necrosis factor (TNFα): induction of TNF receptors on human T cells and TNF-α mediated enhancement of T cell responses. J Immunol. 138:1786-1790.
24. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA. 1985. Activation of human polymorphonuclear neutrophil functions by interferon gamma and tumor necrosis factors. J Immunol 135:2069-2073.
25. Sivaraman S, Venugopal P, Huang X, Gregory SA, Jajeh A, Preisler HD. 1999. Effect of in vitro exposure to interferon alpha on CD20 expression in Chronic Lymphocytic Leukemia cells (CLL). Ann Oncol 10(Suppl 3):abst 222.
26. Sivaraman S, Venugopal P, Ranganathan R, Deshpande CG, X Huang, Jajeh A, Gregory S, O'Brien T, Preisler HD. 2000. Effect of Interferon alpha on CD20 antigen expression of B cell chronic lymphocytic leukemia (B-CLL). Cytokines, Cell Mol Ther (in press).
27. Stashenko P, Nadler LM, Hardy R, Schlossman SF. 1980. Characterization of a human B lymphocyte-specific antigen. J Immunol 125: 1678-1685.
28. Tedder TF, Forsgren A, Boyd AW, Nadler LM et al. 1986. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 16:881-887.
29. Trentin L, Pizzolo G, Zambello R, Agostini C, Morosato L, Sancetta R, Adami F, Vinante F, Chilosi M, Gallati H and Semenzato G.1995. Leukemic cells in hairy cell leukemia and B cell chronic lymphocytic leukemia release soluble TNF receptors. Leukemia 9:1051-1055.
30. Treon SP, Shima Y, Preffer I, Schlossman R, et al. 1999. Interferon gamma induces CD20 expression on multiple myeloma patient and healthy donor plasma cells and B cells and augments binding of rituximab (rituxan) to multiple myeloma plasma cells. Ann Oncol 10(Suppl 3):abstr 104.
31. Venugopal P, Sivaraman S, Huang X, Chopra HK, O'Brien T, Jajeh A, Preisler HD. 2000. Effects of cytokines on CD20 antigen expression in tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 24(5):411-415.
32. Waage A, Espevik T. 1994. TNF receptors in chronic lymphocytic leukemia. Leuk Lymph13:41-46.
33. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. 1999. Cytokine release syndrome in patients with B-CLL and high lymphocyte counts after treatment with anti CD20 antibody (IDEC-C2B8). Blood 94:2217-2224.